Skip to content
Peptide research

Melanotan I

Also known as Afamelanotide · Scenesse · CUV1647 · NDP-MSH
Category
Skin & Cosmetic
Administration routes
Injectable
Regulatory status
FDA-approved

What it is

A linear alpha-MSH analog that binds MC1R to raise eumelanin, sold as an approved implant and also used, outside its approval, for cosmetic tanning. Evidence for EPP photoprotection is solid; quality-of-life and vitiligo gains are moderate; other claims are speculative. Skin darkening is expected, and nausea affected 19% in the FDA trial safety population. Moles need monitoring, and unregulated products carry melanoma case reports. Approved only for EPP; cosmetic tanning relies on unregulated products sold online.

Read Full record

Studied uses & evidence

Studied uses(8)

  • Photoprotection in EPP

    High

    Two blinded, placebo-controlled trials enrolled 168 patients: 74 in the EU and 94 in the US.

  • Eumelanin production without UV

    High

    Skin darkening was recorded as a trial-confirmed effect in vehicle-controlled human studies, without UV exposure.

  • Quality of life improvement in EPP

    Medium

    Quality-of-life gains were a secondary endpoint in RCTs, with further support from a retrospective cohort study.

Evidence limits

Evidence Level
Level 1 — FDA Approved

Two pivotal Phase III multicenter, randomized, double-blind, placebo-controlled trials (168 patients total: 74 EU, 94 US). Additional Phase II/III trials in vitiligo, polymorphic light eruption, and other photodermatoses. FDA approval based on 3 trials totaling 244 adults across 22 US and European sites. Post-marketing observational data from 200-patient German cohort confirms long-term safety.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(9)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Nausea and headache (very common, >10% of patients)

    Moderate
  • Implant site reactions including bruising and discomfort

    High
  • Darkening of existing moles — requires regular dermatologic monitoring for melanocytic changes

    High
  • Diffuse skin hyperpigmentation experienced by nearly all patients

    High
  • Rare serious hypersensitivity reactions including anaphylaxis (post-marketing reports)

    Moderate
  • New melanocytic nevi may develop during treatment

    Low
  • Unregulated melanotan products: 4 case reports of melanoma emergence, unknown purity/dosing, melanocytic changes in moles and dysplastic nevi

    Moderate
  • Safety not established in children, pregnancy/breastfeeding, or patients with liver/kidney impairment

    Moderate
  • Long-term effects of repeated eumelanin stimulation beyond clinical trial durations not fully characterized

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.